Skip to main content

Show 32 results Show all

Building capacity through digital approaches: Can eLearning replace in-person training?

Using eLearning to train health workers on family planning counseling can be an effective training approach, particularly when carefully planned and coordinated to maximize the benefits. On August 26, 2021, the DMPA-SC Access Collaborative hosted this webinar on eLearning for health workers learning to counsel clients on DMPA-SC self-injection in Senegal and Uganda. During the COVID-19 pandemic in 2020, this approach was launched and evaluated in four regions of Senegal and four districts in Uganda.

The findings and recommendations from the experiences in Senegal and Uganda may offer lessons for other countries wishing to implement digital learning approaches. The webinar presenters raised important considerations about stakeholder coordination, internet and technology access, eLearning platforms, establishing training targets, training content, and the important role of post-training supervision.

Institutional Author(s): PATH, JSI, Inc.
Publication date: August, 2021

Toolkit for DMPA-SC monitoring, learning, and evaluation

Data has the power to convey the lived experiences of women and adolescents, highlighting the importance and potential of expanding choices to reduce unmet need for contraception. This monitoring, learning, and evaluation (MLE) toolkit features three tools for dynamic decision-making: A data visualization principles guide, an Excel dashboard how-to guide, and a data use and indicators guide. These are primers on how to create dynamic and visually compelling self-injection program data displays (e.g., dashboards, presentations) that facilitate comprehension and use of self-injection data for family planning program decision-making. While the MLE toolkit was developed with self-injection in mind, many of the principles could be applied to data visualization needs across family planning programs and methods.

We want to hear from you! By completing this short survey, you can help us ensure the tools are meeting the needs of key stakeholders during new product introduction and scale-up. Please contact with any questions or request for assistance.

Institutional Author(s): JSI, Inc., PATH
Publication date: July, 2021

DMPA-SC Supportive supervision toolkit

Supportive supervision plays a critical role to ensure high-performing health workers have the appropriate knowledge, skills, and motivation in order to deliver quality family planning (FP) services and informed choice counseling. This package includes three supportive supervision tools that can be used by regional or district health teams when conducting supervision visits at health facilities that offer FP services:

  1. Supportive supervision checklist to assess provision of family planning counseling
  2. Observation checklist to assess health workers counseling clients on DMPA-SC self-injection
  3. Remote supervision of family planning providers (includes family planning and self-injection)

Tools #1 and #2 can be used together or separately, depending on whether or not the supervision visits include follow-up with providers recently trained to counsel clients on DMPA-SC self-injection.

Tool #3 is intended for use in situations where in-person supervision is not possible; the supervision exercise can be conducted through phone or video. Tool #3 includes guidance and instructions for supervisors who plan to conduct supervision remotely using this tool.

The tools are intended to serve as guides and can be adapted for specific settings as needed. For more information, contact

Institutional Author(s): PATH, JSI, Inc.
Publication date: July, 2021

Unlocking DMPA-SC data-sharing between private pharmacies and ministries of health

This webinar hosted by the DMPA-SC Access Collaborative Learning and Action Networks (LAN) on July 21, 2021 highlighted important considerations for private pharmacies in data collection and reporting on self-care products such as DMPA-SC self-injection. Presenters shared their experiences and lessons from introducing DMPA-SC self-injection through private delivery channels in their respective countries.

Highlights included:

  • The specific types of self-injection data collected across countries.
  • Best practices for engaging and motivating private sector pharmacies and drug shops to provide data to the public sector.
  • Tools used by pharmacies to collect self-injection data.

This virtual discussion encouraged all stakeholders—program implementers, researchers, government officials, health providers, and civil society members—to consider private sector perspectives on data collection and reporting practices, highlighting the importance of good private sector data to inform government policies and strategies for monitoring, regulating health products, and procurement.

Institutional Author(s): PATH, JSI, Inc., inSupply Health, Pharmaceutical Society of Kenya, Pharmaceutical Society of Zambia
Publication date: July, 2021

WHO Consolidated Guideline on Self-Care Interventions for Health

This guidance from the World Health Organization (WHO) aims to provide a people-centred, evidence-based normative guideline that will support individuals, communities, and countries with quality health services and self-care interventions, based on PHC strategies, comprehensive essential service packages and people-centredness. The guidance includes a “strong” recommendation for self-administered injectable contraception, stating that this should be made available as an additional approach to deliver injectable contraception for individuals of reproductive age.

Institutional Author(s): World Health Organization (WHO)
Publication date: June, 2021

Looking back, thinking forward, and scaling up: Insights from the DMPA-SC Access Collaborative

The DMPA-SC Access Collaborative hosted this April 21, 2021 webinar highlighting lessons learned to date through four years of data-driven technical assistance and coordination to ensure that women have increased access to self-injection as a contraceptive option, delivered through informed choice programming. The discussion focused on key topics for the introduction and scale-up of self-injection—and self-care interventions more broadly—at the country level including:

  • Policy and advocacy for new product introduction.
  • How to coordinate scale-up of a new product.
  • Using data to inform program introduction and scale-up.
  • Effective innovations and adaptations in provider training.

This discussion was moderated by Monica Mutesa, Zambia Country Coordinator, DMPA-SC Access Collaborative, PATH. Speakers included:

  • Caitlin Corneliess, Project Director, DMPA-SC Access Collaborative, PATH
  • Adewole Adefalu, Nigeria Country Coordinator, DMPA-SC Access Collaborative, JSI
  • Allen Namagembe, Uganda Deputy Director, DMPA-SC Access Collaborative, PATH
  • Avotiana Rakotomanga, Madagascar Country Coordinator, DMPA-SC Access Collaborative, JSI
  • Alain Kabore, Regional Technical Advisor, DMPA-SC Access Collaborative, PATH

For more information, please contact

Institutional Author(s): PATH, JSI, Inc.
Publication date: April, 2021

Counting on the Private Sector to Understand the Total Market: Considerations for DMPA-SC data collection, reporting and use

In this Making Self-Injection Count workshop session, participants were engaged in a lively discussion and interactive collaboration around the important considerations for private sector data collection and reporting on self-care products such as DMPA-SC. This session began with a short presentation to set the stage on the important role of private sector and data within the context of mixed health systems. Participants joined a moderated discussion with three in-country implementers from Nigeria (DKT), Uganda (PSI) and Zambia (JSI) who shared their experiences and lessons from introducing DMPA SC self-injection and other self-care products through private delivery channels. The session concluded with a facilitated, interactive activity to identify and prioritize private sector data needs.


By the end of the session, participants were able to:

  • Characterize the private sector within the context of the total market for DMPA-SC and other self-care products.
  • Describe the current landscape for provision of DMPA-SC self-injection through the private sector.
  • Identify the unique considerations and feasibility for collecting private sector data within mixed health systems.

Key takeaways

  • The private sector is highly diverse and fragmented, comprised of profit and non-for-profit, formal and informal, domestic and global non-state actors. A total market approach (TMA) considers all channels of service delivery–public and private–to increase equitable and sustainable access to health products and services by maximizing the comparative advantage of all sectors. TMA builds upon market segmentation, using various channels to expand the overall market and meet demand for family planning, particularly where the public sector is not meeting women’s preferences/needs.
  • Aligning and harmonizing data in mixed health systems is complicated. Different types of data are needed at various levels to understand the total market. By taking a holistic perspective–one that considers both the public and private sectors–we can identify the opportunities and gaps that exist at client, provider and systems level to guide policy, program, and investment decisions. Some data is more readily available, such as public sector procurement and distribution trends. However, other data, such as consumer retail price, willingness to pay or volumes of product sold, are often less available due to a variety of reasons, and sometimes require additional research.
  • It is important to engage and understand the perspectives of the private sector when it comes to data collection/reporting desires and needs of governments and other stakeholders.


  • Ariella Bock, Senior Technical Advisor, JSI
  • Mika Bwembya, Health Supply Chain and Total Market Director, USAID DISCOVER Health Project
  • Kimberly Cole, Private Sector Service Delivery Programs, USAID’s Global Health Bureau’s Office of Population and Reproductive Health
  • Tanvi Pandit-Rajani, Private Sector & Health Markets Lead, JSI
  • Christine Prefontaine, Senior Human-Centered Design Advisor, JSI
  • Victoria Webbe, Regional Knowledge Manager, DKT Francophone West and Central Africa

Institutional Author(s): PATH, JSI, Inc.
Publication date: March, 2021

Interim and complementary data solutions

Participants in this Making Self-Injection Count workshop session learned about interim data sources for self-injection data, including Performance Monitoring for Action (PMA) surveys, demographic and health surveys (DHS) surveys, and low-resource, short-term auxiliary data collection systems. This session also highlighted efforts made to collect and use family planning data in humanitarian settings. Presenters addressed general timelines for data access in different countries and evaluated differences in indicators across data sets.


By the end of the session, participants were able to:

  • Describe how questions on self-injection are being incorporated into broader surveys and get a sense of the timeline for when self-injection survey data will become available in select countries.
  • Describe alternative approaches for gathering data on self-care methods, including self-injection, when routine systems are not available.
  • Strategize practical solutions for accessing data in their local setting.

Key takeaways

  • It can take time (one to five years) for new products to be integrated into routine information systems (HMIS/LMIS). While work is underway to integrate self-injection into routine systems, interim and complementary data solutions can fill that missing dataset.
  • Four considerations for interim data collection:
    • Clarity of rationale: Collect data critical for tracking progress and informative for decision- making.
    • Feasibility: use existing systems to the extent possible.
    • Acceptability: aim to make data collection simple for FP focal persons.
    • Institutionalization: collaborate and coordinate with the MOH and other partners, critically reviewing self-injection’s contribution to the method mix with the goal of adapting the HMIS to include SI data.


  • Phil Anglewicz, Principal Investigator, Performance Monitoring for Action (PMA) project
  • Joy Fishel, Senior Survey Coordinator, Demographic and Health Surveys Program
  • Stephen Mawa, Program Management Specialist, UNFPA South Sudan
  • Allen Namagembe, Uganda Country Coordinator, PATH
  • Avotiana Rakotomanga, Madagascar Country Coordinator, JSI
  • Shannon Wood, PMA, Assistant Scientist, Department of Population, Family and Reproductive Health at the Johns Hopkins Bloomberg School of Public Health

Institutional Author(s): PATH, JSI, Inc.
Publication date: March, 2021

What we learned and where we go from here: Making Self-Injection Count workshop

This session wrapped up the Making Self-Injection Count workshop and highlighted key takeaways. Participants had an opportunity to reflect on what they learned and the action steps they have identified to move forward with their work.

Key takeaways

The workshop closed with four calls to action:

  1. Add your country’s data to the global DMPA-SC monitoring system. For more information, email
  2. Request technical assistance from the Access Collaborative.
  3. Organize for action planning with the Access Collaborative’s action planning resources. Action planning can be facilitated on your own or with one of our technical advisors.
  4. Participate in discussions and knowledge exchange through the Learning and Action Networks. Sign up for the LAN newsletter here.


  • Caitlin Corneliess, MPH, Project Director, Access Collaborative

Institutional Author(s): PATH, JSI, Inc.
Publication date: March, 2021

Creating effective data visualizations to support family planning decision-making

This was a hands-on skill-building session during the Making Self-Injection Count workshop in which participants worked with a sample data set in order to create data visualizations using Microsoft Excel. Two versions of the session were offered—a beginner session for participants with limited experience using Excel and data visualizations, and an advanced session for those with more experience. Participants needed a computer with Excel; the dataset and other materials were provided.


By the end of the session, participants were able to:

  • Identify key considerations for developing data visualization products.
  • Build a dynamic and interactive decision-making tools in Excel through a hands-on exercise.
  • Tailor data visualization products to meet the needs of different audiences.

Key takeaways

  • Family planning data must be distilled and easy to understand to enable stakeholders to make decisions.
  • When developing data visualizations, ask the following:
    • Who is your audience?
    • What do they want to know?
    • How will you communicate it?
  • Stakeholders differ in their data needs and visual literacy, and the approach you use should align with the audience’s information needs.


  • Nicole Danfakha, Senior Data Viz Program Officer, JSI
  • Dome Okoku, MLE Advisor, InSupply Health

Institutional Author(s): PATH, JSI, Inc.
Publication date: March, 2021